Table 1

Table 2

Table 3

Table 4

Table 5

Table 6

Table 7

Figure 1

Figure 2

Table 1: Clinical characteristics of the enrolled participants (FAS)

aStudent’s T-test; 2Chi-square test;

Table 2: The primary efficacy endpoint for the improvement of vaginal dryness (FAS)

IQR: Interquartile Range.

Table 3: Improvements of vaginal elasticity, moisture, and secretions (FAS)

Characteristics	Visit	Groups	Frequency count for each point scale					Statistics (p-value)
Characteristics	Visit	Groups	1	2	3	4	5	Statistics (p-value)
Vaginal elasticity	1st visit	Treatment group	0	18	10	10	0	0.292
	1st visit	Control group	0	14	15	7	2	0.292
	Final visit	Treatment group	0	1	22	7	8	0.013
	Final visit	Control group	0	8	13	13	4	0.013
Vaginal moisture	1st visit	Treatment group	2	13	12	11	0	0.967
	1st visit	Control group	3	11	14	9	1	0.967
	Final visit	Treatment group	0	2	16	13	7	0.423
	Final visit	Control group	0	5	19	8	6	0.423
Vaginal secretions	1st visit	Treatment group	8	14	7	9	0	0.968
	1st visit	Control group	8	12	9	9		0.968
	Final visit	Treatment group	1	3	17	11	6	0.507
	Final visit	Control group	0	8	16	9	5	0.507

Table 4: Change of vaginal pH between treatment of control groups (PPS)

Table 5: Improvement of vulvar and vaginal sting, and dyspareunia (FAS)

Characteristic	Visit	Groups	Frequency count for each point scale				Statistics(P)
Characteristic	Visit	Groups	1	2	3	4	Statistics(P)
Vulvar and vaginal sting	1st visit	Treatment group	4	19	13	2	>0.999
	1st visit	Control group	3	20	13	2	>0.999
	Final visit	Treatment group	1	4	20	13	0.882
	Final visit	Control group	1	6	20	11	0.882
Dyspareunia	1st visit	Treatment group	6	13	18	1	0.710
	1st visit	Control group	4	15	16	3	0.710
	Final visit	Treatment group	0	7	22	6	0.648
	Final visit	Control group	1	4	22	8	0.648

Table 6: Symptomatic relief time (FAS)

Table 7: Satisfaction evaluation at the final visit (FAS)